SOURCE: CNS Response

CNS Response

March 01, 2011 10:15 ET

CNS Response Announces Collaborative Agreement With Medco to Assess Impact of Referenced-EEG®

ALISO VIEJO, CA--(Marketwire - March 1, 2011) - CNS Response, Inc. (OTCQB: CNSO), has entered into a collaborative agreement with Medco Research Institute, LLC, to assess the pharmaco-economic benefits of its online Referenced-EEG® (rEEG) database. Medco Research Institute is the research arm of Medco Health Solutions, Inc., the market leader in pharmacy benefits management.

"Our collaborative agreement with Medco provides another opportunity for an outside, third party to assess the benefits of rEEG as an information tool to assist physicians in treating patients with mental health issues," said Mike Darkoch, executive vice president of CNS Response. "This project will include a pharmaco-economic study of rEEG patients over the past ten years, many of whom received medications dispensed by Medco."

"Trial and error pharmacotherapy has become the dominant treatment model for people who have failed on two or more medications, with enormous implications for healthcare costs," said CNS Response CEO George Carpenter. "While medical professionals already indicate that our reports help them reduce trial and error, we expect the depth of Medco's data resources and analytic expertise to yield additional insights on the efficacy of rEEG from a clinical and economic perspective."

Developed by CNS Response, rEEG is an online reference database that offers medical professionals objective, personalized statistical data on their patients' neurophysiology. While most physicians in other disciplines are able to base their treatment decisions on objective data gathered from EKGs, MRIs, blood tests and similar procedures, such advances have not previously been available to medical professionals treating mental illness. The data provided by CNS Response enables medical professionals to better understand an individual patient's neurophysiology, thereby reducing medication trial and error.

In a recent study published by the Journal of Psychiatric Research, physicians who used rEEG achieved a 65 percent success rate in treating patients with depression, compared to a 39 percent success rate with the control group. Those results were even more significant because the subjects in the study, selected through a randomized process, had failed an average of four previous treatments for depression. The Journal of Psychiatric Research study article can be found online at

About CNS Response

CNS Response provides reference data and analytic tools for clinicians and researchers, using a novel neurometric database called Referenced-EEG® (rEEG). Developed by physicians as a platform to exchange objective, neurophysiology-based data on medication response and outcomes, physicians using rEEG in clinical trials have consistently reduced their use of trial and error pharmacotherapy. To read more about the benefits of this patented technology for patients, physicians and payers, please visit the CNS Response website,

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.

Contact Information

  • Investor Relations:
    Marty Tullio
    Managing Partner
    McCloud Communications, LLC
    Email Contact

    Media Relations:
    Joyce Johannson
    Johannson Communications
    612.927.4543 (office)
    612.845.3080 (cell)
    Email Contact